Wedbush Analysts Raise Earnings Estimates for BCRX

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Investment analysts at Wedbush raised their Q3 2025 earnings per share estimates for shares of BioCryst Pharmaceuticals in a research report issued to clients and investors on Tuesday, October 14th. Wedbush analyst L. Chico now anticipates that the biotechnology company will post earnings per share of $0.08 for the quarter, up from their previous forecast of $0.07. Wedbush currently has a “Outperform” rating and a $18.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals’ FY2025 earnings at $0.15 EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.12. The company had revenue of $163.35 million during the quarter, compared to the consensus estimate of $149.59 million. During the same quarter in the prior year, the business earned ($0.06) earnings per share. The firm’s revenue for the quarter was up 49.5% on a year-over-year basis.

BCRX has been the topic of several other reports. Needham & Company LLC lifted their target price on BioCryst Pharmaceuticals from $17.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday. Cantor Fitzgerald lifted their target price on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday. Evercore ISI reiterated an “in-line” rating and set a $8.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. TD Cowen assumed coverage on BioCryst Pharmaceuticals in a report on Wednesday. They set a “buy” rating and a $30.00 target price on the stock. Finally, Zacks Research upgraded BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $19.18.

BioCryst Pharmaceuticals Stock Up 6.1%

NASDAQ:BCRX opened at $6.81 on Wednesday. The stock’s fifty day simple moving average is $7.90 and its 200-day simple moving average is $8.65. The firm has a market capitalization of $1.43 billion, a P/E ratio of -37.83, a P/E/G ratio of 1.28 and a beta of 1.05. BioCryst Pharmaceuticals has a 12-month low of $6.00 and a 12-month high of $11.31.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of BCRX. Headlands Technologies LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the first quarter valued at about $32,000. GAMMA Investing LLC grew its holdings in BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 5,449 shares during the period. New Age Alpha Advisors LLC bought a new position in BioCryst Pharmaceuticals during the first quarter worth about $62,000. Family Legacy Financial Solutions LLC bought a new position in BioCryst Pharmaceuticals during the second quarter worth about $72,000. Finally, Allspring Global Investments Holdings LLC bought a new position in BioCryst Pharmaceuticals during the first quarter worth about $79,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

Insider Activity

In related news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the sale, the director owned 65,352 shares of the company’s stock, valued at approximately $556,145.52. The trade was a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 5.10% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.